These subtypes include the ER+/PR+/HER2+, ER+/PR+/HER2−, ER−/PR−/HER2+ and the triple-negative ER−/PR−/HER2− breast cancers, which differ in prognosis and the factors that influence their occurrence [9]. This evidence concerns the gene PGR and breast cancer.